Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.

Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, Takahashi M, Tsurutani J, Iwatani T, Kitada M, Tada H, Mori N, Higuchi T, Iwasa T, Araki K, Koizumi K, Hasegawa H, Uchida Y, Morita S, Masuda N

Open source

DOI: 10.1200/jco-24-01888
Published: 2025 Apr 10
Container: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco-24-01888,
  title = {Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.},
  author = {Yamashita T and Saji S and Takano T and Naito Y and Tsuneizumi M and Yoshimura A and Takahashi M and Tsurutani J and Iwatani T and Kitada M and Tada H and Mori N and Higuchi T and Iwasa T and Araki K and Koizumi K and Hasegawa H and Uchida Y and Morita S and Masuda N},
  year = {2025},
  journal = {Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  doi = {10.1200/jco-24-01888},
  url = {https://doi.org/10.1200/jco-24-01888}
}

RIS

TY  - JOUR
TI  - Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.
AU  - Yamashita T
AU  - Saji S
AU  - Takano T
AU  - Naito Y
AU  - Tsuneizumi M
AU  - Yoshimura A
AU  - Takahashi M
AU  - Tsurutani J
AU  - Iwatani T
AU  - Kitada M
AU  - Tada H
AU  - Mori N
AU  - Higuchi T
AU  - Iwasa T
AU  - Araki K
AU  - Koizumi K
AU  - Hasegawa H
AU  - Uchida Y
AU  - Morita S
AU  - Masuda N
PY  - 2025
JO  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
DO  - 10.1200/jco-24-01888
UR  - https://doi.org/10.1200/jco-24-01888
ER  -

APA

T, Y., S, S., T, T., Y, N., M, T., A, Y., M, T., J, T., T, I., M, K., H, T., N, M., T, H., T, I., K, A., K, K., H, H., Y, U., S, M., & N, M. (2025). Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2-Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. https://doi.org/10.1200/jco-24-01888

Source records

pubmed · retrieved 2026-09-27T15:03:08.578Z